{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:35:28Z","timestamp":1794436528243,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Assessement of the responder and non-responder rate to consecutive monoclonal CGRP-antibody (CGRP-mAb) treatment, the presence of side effects, analysis of predictors of response and loss-of-effectiveness evaluation over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective analysis including 171 patients with episodic (EM) or chronic migraine (CM), who received one, two or three different CGRP-mAbs. Non-response was defined as \u2264\u200950% reduction of monthly migraine days (MMDs) in EM and \u2264\u200930% reduction of MMDs in CM after 3 months of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>123 (71.9%) responded to the first mAb. Side effects led to treatment discontinuation in 9 (5.3%) patients. Of the 26 patients who did not respond to the first mAb or experienced a loss of efficacy over time, 11 (42.3%) responded to the second and two (28.6%) of 7 to the third monoclonal antibody. Poor response to therapy was associated with a higher monthly migraine frequency (p\u2009=\u20090.028), a higher number of prior preventive migraine therapies (p\u2009=\u20090.011) and medication overuse (p\u2009=\u20090.022).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings support mAb-class switch in non-responders or in patients experiencing a loss of effectiveness. The use of a third CGRP-mAb could be beneficial for some patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03203-9","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T06:02:33Z","timestamp":1682661753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series"],"prefix":"10.1186","volume":"23","author":[{"given":"Katharina","family":"Kaltseis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alois","family":"Schiefecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Broessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"3203_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/304129a0","volume":"304 5922","author":"MG Rosenfeld","year":"1983","unstructured":"Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983;304 5922:129\u201335. https:\/\/doi.org\/10.1038\/304129a0.","journal-title":"Nature"},{"key":"3203_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410230214","volume":"23 2","author":"PJ Goadsby","year":"1988","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23 2:193\u20136. https:\/\/doi.org\/10.1002\/ana.410230214.","journal-title":"Ann Neurol"},{"key":"3203_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33 1","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33 1:48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109.","journal-title":"Ann Neurol"},{"key":"3203_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319 19","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of Fremanezumab compared with placebo for Prevention of episodic migraine: a Randomized Clinical Trial. JAMA. 2018;319 19:1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853.","journal-title":"JAMA"},{"key":"3203_CR5","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377 22","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med. 2017;377 22:2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1705848.","journal-title":"N Engl J Med"},{"key":"3203_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75 9","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75 9:1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"issue":"3","key":"3203_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"key":"3203_CR8","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94 13","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94 13:e1365\u2013e77. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurology"},{"key":"3203_CR9","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91 24","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91 24:e2211\u2013e21. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"key":"3203_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16 6","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16 6:425\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2.","journal-title":"Lancet Neurol"},{"key":"3203_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377 22","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive treatment of chronic migraine. N Engl J Med. 2017;377 22:2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"key":"3203_CR12","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95 18","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95 18:e2487\u2013e99. https:\/\/doi.org\/10.1212\/WNL.0000000000010600.","journal-title":"Neurology"},{"key":"3203_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/head.14218","author":"J Gladstone","year":"2021","unstructured":"Gladstone J, Chhibber S, Minhas J, Neish CS, Power GS, Lan Z, et al. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: retrospective real-world study. Headache. 2021. https:\/\/doi.org\/10.1111\/head.14218.","journal-title":"Headache"},{"key":"3203_CR14","doi-asserted-by":"publisher","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al. Erenumab in highly therapy-refractory migraine patients: first german real-world evidence. J Headache Pain. 2020;21(1:84). https:\/\/doi.org\/10.1186\/s10194-020-01151-0.","DOI":"10.1186\/s10194-020-01151-0"},{"key":"3203_CR15","doi-asserted-by":"publisher","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1:61). https:\/\/doi.org\/10.1186\/s10194-020-01127-0.","DOI":"10.1186\/s10194-020-01127-0"},{"key":"3203_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35 8","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of Topiramate and Monoclonal antibodies against CGRP or its receptor for the Prophylaxis of episodic migraine: a systematic review with Meta-analysis. CNS Drugs. 2021;35 8:805\u201320. https:\/\/doi.org\/10.1007\/s40263-021-00834-9.","journal-title":"CNS Drugs"},{"key":"3203_CR17","doi-asserted-by":"publisher","unstructured":"Frank F, Ulmer H, Sidoroff V, Broessner G. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia. 2021;3331024211018137. https:\/\/doi.org\/10.1177\/03331024211018137.","DOI":"10.1177\/03331024211018137"},{"key":"3203_CR18","doi-asserted-by":"publisher","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2021;3331024211053571. https:\/\/doi.org\/10.1177\/03331024211053571.","DOI":"10.1177\/03331024211053571"},{"key":"3203_CR19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40 13","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020;40 13:1511\u201322. https:\/\/doi.org\/10.1177\/0333102420946725.","journal-title":"Cephalalgia"},{"key":"3203_CR20","doi-asserted-by":"publisher","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia. 2021;3331024211048765. https:\/\/doi.org\/10.1177\/03331024211048765.","DOI":"10.1177\/03331024211048765"},{"issue":"2","key":"3203_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.13729","volume":"60","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, May A. Non-responders to treatment with antibodies to the CGRP-Receptor May profit from a switch of antibody class. Headache. 2020;60(2):469\u201370. https:\/\/doi.org\/10.1111\/head.13729.","journal-title":"Headache"},{"key":"3203_CR22","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38 1:1-211; doi: https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"1\u20132","key":"3203_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1\u20132):48\u201356. https:\/\/doi.org\/10.1016\/j.jns.2013.05.003.","journal-title":"J Neurol Sci"},{"key":"3203_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/wnl.55.5.629","volume":"55 5","author":"RB Lipton","year":"2000","unstructured":"Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55 5:629\u201335. https:\/\/doi.org\/10.1212\/wnl.55.5.629.","journal-title":"Neurology"},{"key":"3203_CR25","doi-asserted-by":"publisher","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain. 2022;23(1:67). https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","DOI":"10.1186\/s10194-022-01431-x"},{"key":"3203_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61 7","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Society BoDotAH. The american Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61 7:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"3203_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59 1","author":"AH Society","year":"2019","unstructured":"Society AH. The american Headache Society position Statement on integrating New Migraine Treatments into clinical practice. Headache. 2019;59 1:1\u201318. https:\/\/doi.org\/10.1111\/head.13456.","journal-title":"Headache"},{"key":"3203_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nrneurol.2012.13","volume":"8 3","author":"HC Diener","year":"2012","unstructured":"Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine\u2013classification, characteristics and treatment. Nat Rev Neurol. 2012;8 3:162\u201371. https:\/\/doi.org\/10.1038\/nrneurol.2012.13.","journal-title":"Nat Rev Neurol"},{"key":"3203_CR29","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392 10161","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392 10161:2280\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0.","journal-title":"Lancet"},{"key":"3203_CR30","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38 11","author":"U Reuter","year":"2021","unstructured":"Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM, et al. Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER Trial. Adv Ther. 2021;38 11:5465\u201383. https:\/\/doi.org\/10.1007\/s12325-021-01911-7.","journal-title":"Adv Ther"},{"key":"3203_CR31","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394 10203","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394 10203:1030\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4.","journal-title":"Lancet"},{"key":"3203_CR32","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39 10","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39 10:1284\u201397. https:\/\/doi.org\/10.1177\/0333102419840780.","journal-title":"Cephalalgia"},{"key":"3203_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/0333102420983282","volume":"41 5","author":"M Bhakta","year":"2021","unstructured":"Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD. Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia. 2021;41 5:499\u2013514. https:\/\/doi.org\/10.1177\/0333102420983282.","journal-title":"Cephalalgia"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03203-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03203-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03203-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T06:02:38Z","timestamp":1682661758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03203-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3203"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03203-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KK, VF, CE have no potential conflict of interests to declare. FF reports personal fees from Novartis AG, personal fees from Eli Lilly and Company, and personal fees from TEVA Pharmaceutics, outside of the submitted work. AS reports personal fees from TEVA pharmaceutics, outside the submitted work. GB has received unrestricted grants, honoraria, personal fees, and travel grants from Allergan, AMGEN, Menarini, Pfizer, Linde AG, Astra Zeneca, St. Jude Medical, Reckitt Benkiser, Novartis, TEVA, Fresenius, Janssen Cilag, Lundbeck and Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the local ethics committee of the Medical University of Innsbruck (1056\/2022) and the research was conducted in accordance with the Declaration of Helsinki. The need for informed consent was waived by the ethics committee of the Medical University of Innsbruck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"174"}}